Despite quantitative variations across algorithms, we observed a consistent cross-method trend: elevated CGB5 expression positively correlated with tumor-progressive immune microenvironment phenotypes, including increased stromal content (ESTIMATE StromalScore) and immunosuppressive subtypes (e.g., C4 lymphocyte-depleted subtype) (Figures 6, 7). The gene discussed is CGB5; the disease is neoplasm.